In a report released today, Soumit Roy from JonesTrading maintained a Hold rating on Aileron Therapeutics (ALRN – Research Report). The company’s shares opened today at $0.21.
Roy covers the Healthcare sector, focusing on stocks such as Curis, Aeglea Biotherapeutics, and AVEO Pharma. According to TipRanks, Roy has an average return of 6.7% and a 32.49% success rate on recommended stocks.
The analyst consensus on Aileron Therapeutics is currently a Hold rating.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $0.94 and a one-year low of $0.13. Currently, Aileron Therapeutics has an average volume of 1.14M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aileron Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead products candidate, ALRN-6924 which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky in June 2005 and is headquartered in Cambridge, MA.
Read More on ALRN:
- Aileron Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
- Aileron Therapeutics presented details from Phase 1 study of ALRN-6924
- Aileron Therapeutics Presents Results from Phase 1 Study in Healthy Volunteers Demonstrating ALRN-6924 Induced Cell Cycle Arrest in Bone Marrow Stem Cells and Hair Follicles at EORTC-NCI-AACR International Conference
- Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022
- Aileron Therapeutics to present non-clinical data on ALRN-6924
